Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.

Lincoff AM, Tardif JC, Neal B, Nicholls SJ, Rydén L, Schwartz GG, Malmberg K, Buse JB, Henry RR, Wedel H, Weichert A, Cannata R, Grobbee DE.

Am Heart J. 2013 Sep;166(3):429-34. doi: 10.1016/j.ahj.2013.05.013.

PMID:
24016490
2.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.

Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE; AleCardio Investigators..

JAMA. 2014 Apr 16;311(15):1515-25. doi: 10.1001/jama.2014.3321.

PMID:
24682069
3.

Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.

Erdmann E, Califf R, Gerstein HC, Malmberg K, Ruilope L, Schwartz GG, Wedel H, Volz D, Ditmarsch M, Svensson A, Bengus M.

Am Heart J. 2015 Jul;170(1):117-22. doi: 10.1016/j.ahj.2015.03.021.

PMID:
26093872
4.

Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.

Cavender MA, Lincoff AM.

Am J Cardiovasc Drugs. 2010;10(4):209-16. doi: 10.2165/11539500-000000000-00000.

PMID:
20653327
5.
6.

PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.

Wilding JP.

Diabetes Obes Metab. 2012 Nov;14(11):973-82. doi: 10.1111/j.1463-1326.2012.01601.x. Review.

PMID:
22443197
7.

Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.

Ruilope L, Hanefeld M, Lincoff AM, Viberti G, Meyer-Reigner S, Mudie N, Wieczorek Kirk D, Malmberg K, Herz M.

BMC Nephrol. 2014 Nov 18;15:180. doi: 10.1186/1471-2369-15-180.

8.

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

Clin Ther. 2005 Aug;27(8):1181-95.

PMID:
16199244
9.

Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.

Herz M, Gaspari F, Perico N, Viberti G, Urbanowska T, Rabbia M, Wieczorek Kirk D.

Int J Cardiol. 2011 Sep 1;151(2):136-42. doi: 10.1016/j.ijcard.2010.08.037.

PMID:
20837369
10.

Efficacy, safety and tolerability of aleglitazar in patients with type 2 diabetes: pooled findings from three randomized phase III trials.

Henry RR, Buse JB, Wu H, Durrwell L, Mingrino R, Jaekel K, El Azzouzi B, Andjelkovic M, Herz M.

Diabetes Obes Metab. 2015 Jun;17(6):560-5. doi: 10.1111/dom.12455.

PMID:
25728612
11.

Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.

Sanwald-Ducray P, Liogier D'ardhuy X, Jamois C, Banken L.

Clin Pharmacol Ther. 2010 Aug;88(2):197-203. doi: 10.1038/clpt.2009.259.

PMID:
20336066
12.

No evidence of QT prolongation with supratherapeutic doses of aleglitazar.

Sturm S, Bentley D, Jordan P, Russell-Yarde F, Ruf T.

J Cardiovasc Pharmacol. 2012 Mar;59(3):288-97. doi: 10.1097/FJC.0b013e3182411e67.

PMID:
22113345
13.

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.

Hansen BC, Tigno XT, Bénardeau A, Meyer M, Sebokova E, Mizrahi J.

Cardiovasc Diabetol. 2011 Jan 20;10:7. doi: 10.1186/1475-2840-10-7.

14.
15.
16.

Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk.

Younk LM, Uhl L, Davis SN.

Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):753-63. doi: 10.1517/17425255.2011.579561. Review.

PMID:
21521130
17.

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive Investigators..

Lancet. 2005 Oct 8;366(9493):1279-89.

PMID:
16214598
18.

EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.

White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F.

Am Heart J. 2011 Oct;162(4):620-626.e1. doi: 10.1016/j.ahj.2011.08.004.

PMID:
21982652
19.

Acute coronary syndromes: Aleglitazar trial findings reported.

Mearns BM.

Nat Rev Cardiol. 2014 Jun;11(6):311. doi: 10.1038/nrcardio.2014.53. No abstract available.

PMID:
24736759
20.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721.

PMID:
19145003
Items per page

Supplemental Content

Support Center